Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7262 and Enlicitide in Adults With Elevated Lipoprotein(a)
NCT07614984Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Countries
- 9
01
Overview
A Phase 2 trial of gefapixant in elevated lipoprotein(a) (Lp(a)), sponsored by Merck & Co.. Started Jun 2026; status: recruiting.
02
Drugs
gefapixant
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT07614984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614984.